Morgan Stanley set a €86.00 ($100.00) price objective on Bayer (FRA:BAYN) in a research note released on Tuesday, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.
Other research analysts also recently issued research reports about the stock. Berenberg Bank set a €75.00 ($87.21) price target on shares of Bayer and gave the company a neutral rating in a report on Friday, November 1st. Sanford C. Bernstein set a €90.00 ($104.65) price target on shares of Bayer and gave the company a buy rating in a report on Wednesday, October 30th. Nord/LB set a €64.00 ($74.42) price target on shares of Bayer and gave the company a neutral rating in a report on Wednesday, October 30th. Barclays set a €85.00 ($98.84) price target on shares of Bayer and gave the company a buy rating in a report on Friday, October 25th. Finally, JPMorgan Chase & Co. set a €69.00 ($80.23) price target on shares of Bayer and gave the company a neutral rating in a report on Monday, October 28th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have assigned a buy rating to the company’s stock. Bayer presently has a consensus rating of Hold and a consensus price target of €80.47 ($93.57).
Shares of Bayer stock traded up €0.06 ($0.07) during midday trading on Tuesday, reaching €70.43 ($81.90). 2,316,728 shares of the company’s stock traded hands. The company’s 50 day simple moving average is €66.55 and its 200 day simple moving average is €61.60. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
See Also: What is a Fibonacci Channel?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.